摘要
目的探讨急性加重期慢性阻塞性肺疾病（AECOPD）合并呼吸衰竭患者应用盐酸氨溴索（沐舒坦）的临床疗效。方法研究对象选取2014年10月-2015年10月间于本院呼吸科接受治疗的62例AECOPD合并Ⅱ型呼吸衰竭患者,回顾性将入选病例分为对照组和研究组各31例,其中对照组行常规治疗,研究组在此基础上静脉滴注沐舒坦,对两组患者的临床疗效、相关指标（肺功能和血气）及不良反应情况进行比较。结果治疗前两组患者在血气及肺功能指标上比较差异无显著性（P〉0.05）,经过一个疗程的治疗后,两组患者均有不同程度的改善情况。但研究组相关指标改善程度显著优于对照组（P〈0.05）。对照组无效4例,治疗有效率为87.1%,而研究组无效2例,治疗有效率为93.5%,两组比较差异有显著性（P〈0.05）。结论沐舒坦治疗AECOPD合并呼吸衰竭患者疗效显著,有利于血气指标及肺功能指标的恢复,且安全性好,临床值得推广运用。
Objective To discuss the efficacy of ambroxol（ Mucosolvan） in the acute stage of chronic obstructive pulmonary disease（ AECOPD） with respiratory failure. Methods 62 cases of AECOPD associated with type II respiratory failure from October 2014 to October 2015 accepted treatment in respiratory department of our hospital,were divided into the study group and the control group（ 31 cases in each group）,the control group received routine treatment,the study group received intravenous infusion of Ambroxol.Clinical curative effect of two groups of patients,related lung function and blood indexes and adverse reactions were compared. Results The indexes of blood gas and pulmonary function of two groups before treatment had no significant difference（ P〉0.05）,but had different degrees after a course of treatment. The related indicators in the study group improved significantly better than control group,the difference was statistically significant（ P〈0.05）.The control group had 4 ineffective cases,with effective rate of 87.1%,while the study group had 2 ineffective cases,with effective rate of 93.5%,the difference between the two groups was statistically significant（ P〈0.05）. Conclusion Mucosolvan is effective and safe in AECOPD with respiratory failure,beneficial to the recovery of blood gas index and lung function index,which is worthy of clinical application.
出处
《中南医学科学杂志》
CAS
2016年第5期554-556,共3页
Medical Science Journal of Central South China
关键词
慢性阻塞性肺疾病急性期
沐舒坦
呼吸衰竭
疗效
acute exacerbation of chronic obstructive pulmonary disease
Mucosolvan
respiratory failure
curative effect
